Related Experiment Video
Updated: May 11, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and
1From the Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Abstract:
There is no doubt that more therapeutic progress has been achieved during the last 3 years for patients with metastatic castration-resistant prostate cancer (mCRPC) than during the previous 30 years. During this limited time frame, not only have six compounds (sipuleucel-T, cabazitaxel, denosumab, abiraterone, radium-223, and enzalutamide, listed in chronologic order) yielded positive results in phase III trials, we have also learned that their mechanisms of action are different, making it quite likely that part of their anticancer activity may be incremental. Most of these agents have already been approved. Further progress may well soon complete this recently enlarged armamentarium, with important trials testing new agents derived from existing families of compounds (new endocrine therapies, new immunotherapies, etc.) and exploring the activity of new families of agents (tyrosine kinase inhibitors such as cabozantinib, inhibitors of chaperone proteins like OGX-O11 and OGX-427). The availability of these agents creates a new major challenge for those who conduct clinical research in mCRPC. Will we be able to personalize therapy based on the biology of the individual's tumor, as we are already doing in other neoplasms?
Insights
Recent advancements offer new treatments for metastatic castration-resistant prostate cancer (mCRPC). The focus is shifting towards personalized therapy based on individual tumor biology.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) has seen significant therapeutic progress in the last three years, surpassing the previous thirty years.
- Six compounds, including sipuleucel-T, cabazitaxel, denosumab, abiraterone, radium-223, and enzalutamide, have demonstrated positive results in phase III trials.
Purpose of the Study:
- To review the recent therapeutic advancements in mCRPC.
- To discuss the potential for personalized therapy in mCRPC based on tumor biology.
Main Methods:
- Review of phase III trial results for newly approved mCRPC agents.
- Analysis of the mechanisms of action for these novel compounds.
- Discussion of ongoing and future clinical trials for mCRPC.
Main Results:
- Six agents (sipuleucel-T, cabazitaxel, denosumab, abiraterone, radium-223, enzalutamide) have shown efficacy in phase III trials for mCRPC.
- These agents possess diverse mechanisms of action, suggesting potential for incremental anticancer activity.
- Most of these agents are already approved, expanding the treatment armamentarium.
Conclusions:
- The landscape of mCRPC treatment has been rapidly transformed by new therapeutic options.
- Future research directions include developing new agents and exploring personalized treatment strategies based on tumor-specific biology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...